title: Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
authors.affiliation: Department of Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA. jonathan_a_lee@lilly.com
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Lee
authors.forename: Mark T
authors.initials: MT
authors.lastname: Uhlik
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Moxham
authors.forename: Dirk
authors.initials: D
authors.lastname: Tomandl
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Sall
mesh_terms: D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D057225:Data Mining; D016208:Databases, Factual; D017277:Drug Approval; D016503:Drug Delivery Systems / Q000639:trends; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D004345:Drug Industry / Q000379:methods / Q000639:trends*; D004354:Drug Screening Assays, Antitumor; D023281:Genomics; D057166:High-Throughput Screening Assays / Q000379:methods; D006801:Humans; D051379:Mice; D012106:Research / Q000639:trends*; D013329:Structure-Activity Relationship
chemical_list: D020533:Angiogenesis Inhibitors